Sign In
Buy TXG
$47.27
-2.16 (-4.37%)
At Close: Jul 31, 2026
10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q2 2022 Results - Earnings Call Transcript
08:49pm, Monday, 08'th Aug 2022
10x Genomics, Inc. (NASDAQ:TXG ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Cassie Corneau - Investor Relations and Strategic Finance Serge Saxonov - Chief Executi
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
08:20pm, Monday, 08'th Aug 2022
10x Genomics (TXG) delivered earnings and revenue surprises of -42.50% and 0.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Torex Gold Resources' (TORXF) CEO Jody Kuzenko on Q2 2022 Results - Earnings Call Transcript
11:10am, Saturday, 06'th Aug 2022
Torex Gold Resources, Inc. (OTCPK:TORXF) Q2 2022 Earnings Conference Call August 4, 2022 9:00 AM ET Company Participants Dan Rollins - SVP, Corporate Development & IR Jody Kuzenko - President & CEO An
Analysts Estimate 10x Genomics (TXG) to Report a Decline in Earnings: What to Look Out for
11:37am, Monday, 01'st Aug 2022
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments
12:23pm, Wednesday, 27'th Jul 2022
Cytek and 10x Genomics both offer single cell visualization tools, a growing and important field in modern medicine. However, each company sees huge differences in popularity, financial performance, a
10x Genomics stock suffering record drop toward record low after revenue warnings prompts downgrade
11:09am, Friday, 15'th Jul 2022
Shares of 10x Genomics Inc. TGX, -4.32% plunged 22.3% in active morning trading Friday, putting them on track to suffer a record one-day drop to a record low Friday, after the biotechnology company's
10X Genomics Reports Q2 Preliminary Revenues, Shares Plummet On Missing Street Expectation
05:03pm, Thursday, 14'th Jul 2022
10X Genomics Inc (NASDAQ: TXG) reported preliminary second-quarter revenue is expected to be ~$114.5 million, a decrease of 1% year-over-year, below the consensus of $127.7 million. The company see
10x Genomics stock falls as revenue forecast disappoints
04:31pm, Thursday, 14'th Jul 2022
Shares of 10x Genomics Inc. TXG, -7.74% fell in the extended session Thursday after the biotech company said it expects second-quarter revenue to come in below Wall Street expectations. 10x Genomics s
3 Gene Sequencing Stocks With Potential to Gain in 2H22
10:45am, Wednesday, 13'th Jul 2022
Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.
7 Stocks to Buy That Could Make You a Millionaire
07:00am, Thursday, 23'rd Jun 2022
These seven of the best stocks to buy in June. TXG, BRKR, ETSY, PODD, MAR, RH and SEDG can make excellent investments.
3 Cathie Wood Stocks That Could Deliver Monster Returns
09:00am, Saturday, 04'th Jun 2022
Here's why our roundtable likes 10x Genomics, Beam Therapeutics, and Recursion Pharmaceuticals.
My Favorite Biotech
04:00pm, Friday, 13'th May 2022
Here's why three Fool.com contributors love 10x Genomics, Axsome Therapeutics, and Doximity.
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates
08:18pm, Wednesday, 04'th May 2022
10x Genomics (TXG) delivered earnings and revenue surprises of -2.70% and 1.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q1 2022 Results - Earnings Call Transcript
08:02pm, Wednesday, 04'th May 2022
10x Genomics, Inc. (NASDAQ:TXG ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Cassie Corneau - Investor Relations and Strategic Finance Serge Saxonov - Chief Executive
This Chart Is Why I'm Holding This Stock for the Next Decade
08:25am, Wednesday, 20'th Apr 2022
This biotech's products are a must-have for scientists.
